EA202191545A1 - Кристаллические формы соединения для лечения или профилактики подагры или гиперурикемии - Google Patents
Кристаллические формы соединения для лечения или профилактики подагры или гиперурикемииInfo
- Publication number
- EA202191545A1 EA202191545A1 EA202191545A EA202191545A EA202191545A1 EA 202191545 A1 EA202191545 A1 EA 202191545A1 EA 202191545 A EA202191545 A EA 202191545A EA 202191545 A EA202191545 A EA 202191545A EA 202191545 A1 EA202191545 A1 EA 202191545A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- hyperuricemia
- gut
- prevention
- compounds
- treatment
- Prior art date
Links
- 201000001431 Hyperuricemia Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- ZYHWDBVIUWBPCO-QFFDRWTDSA-N BrC1=C(C(=CC(=C1)C(=O)C1=C(OC2=C1C(=C(C(=C2[2H])[2H])[2H])[2H])C(C)O)Br)O Chemical compound BrC1=C(C(=CC(=C1)C(=O)C1=C(OC2=C1C(=C(C(=C2[2H])[2H])[2H])[2H])C(C)O)Br)O ZYHWDBVIUWBPCO-QFFDRWTDSA-N 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018119567 | 2018-12-06 | ||
| PCT/US2019/064784 WO2020118113A1 (en) | 2018-12-06 | 2019-12-05 | Crystalline forms of a compound for treating or preventing gout or hyperuricemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202191545A1 true EA202191545A1 (ru) | 2021-10-28 |
Family
ID=70974392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202191545A EA202191545A1 (ru) | 2018-12-06 | 2019-12-05 | Кристаллические формы соединения для лечения или профилактики подагры или гиперурикемии |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12145917B2 (https=) |
| EP (1) | EP3890723A4 (https=) |
| JP (2) | JP2022511800A (https=) |
| KR (1) | KR102946486B1 (https=) |
| CN (1) | CN113226302B (https=) |
| AU (1) | AU2019394974B2 (https=) |
| BR (1) | BR112021010708A2 (https=) |
| EA (1) | EA202191545A1 (https=) |
| IL (1) | IL283663B2 (https=) |
| SG (1) | SG11202105745UA (https=) |
| TW (1) | TWI828817B (https=) |
| WO (1) | WO2020118113A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016105499A1 (en) | 2014-12-23 | 2016-06-30 | Intellectual Property Associates, Llc | Methods and formulations for transdermal administration |
| CN113214198B (zh) | 2016-07-18 | 2022-12-23 | 广州瑞安博医药科技有限公司 | 用于治疗或预防与痛风或高尿酸血症相关的症状的化合物、组合物和方法 |
| EP3681479B1 (en) | 2017-09-15 | 2024-01-31 | Dyve Biosciences, Inc. | Sodium bicarbonate for use in the treatment of gout and related disorders |
| CA3121624A1 (en) | 2018-12-06 | 2020-06-11 | Arthrosi Therapeutics, Inc. | Methods for treating or preventing gout or hyperuricemia |
| US12145917B2 (en) | 2018-12-06 | 2024-11-19 | Arthrosi Therapeutics, Inc. | Crystalline forms of a compound for treating or preventing gout or hyperuricemia |
| EP3968989A4 (en) * | 2019-05-14 | 2022-12-28 | Arthrosi Therapeutics, Inc. | COMPOUND FOR TREATMENT OF GOUT OR HYPERURICEMIA |
| WO2021252630A1 (en) * | 2020-06-10 | 2021-12-16 | Arthrosi Therapeutics, Inc. | Methods for treating or preventing chronic kidney disease |
| US20250066316A1 (en) * | 2021-12-02 | 2025-02-27 | Arthrosi Therapeutics, Inc. | Crystalline forms of a compound for treating or preventing gout or hyperuricemia |
| CN118974028A (zh) * | 2021-12-30 | 2024-11-15 | 广州瑞安博医药科技有限公司 | 用于治疗痛风或高尿酸血症的化合物的制备 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| US4624848A (en) | 1984-05-10 | 1986-11-25 | Ciba-Geigy Corporation | Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use |
| US4968509A (en) | 1987-07-27 | 1990-11-06 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
| IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
| WO1992018106A1 (fr) | 1991-04-16 | 1992-10-29 | Nippon Shinyaku Co., Ltd. | Procede de production d'une dispersion solide |
| HU227530B1 (en) | 1991-11-22 | 2011-07-28 | Warner Chilcott Company | Delayed-release compositions containing risedronate and process for their production |
| US5461140A (en) | 1992-04-30 | 1995-10-24 | Pharmaceutical Delivery Systems | Bioerodible polymers for solid controlled release pharmaceutical compositions |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| JP2616252B2 (ja) | 1992-10-16 | 1997-06-04 | 日本新薬株式会社 | ワックスマトリックスの製法 |
| US5686105A (en) | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| JPH11505258A (ja) | 1995-05-17 | 1999-05-18 | セダーシナイ メディカル センター | 小腸における消化および吸収を改善させる脂肪酸を含む組成物 |
| DE19624292A1 (de) | 1996-06-18 | 1998-01-02 | Merckle Gmbh | Verfahren und Zwischenprodukte zur Herstellung von 1'-Hydroxybenzbromaron |
| US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| US6465014B1 (en) | 2001-03-21 | 2002-10-15 | Isp Investments Inc. | pH-dependent sustained release, drug-delivery composition |
| EP1767531A4 (en) | 2004-06-10 | 2011-01-05 | Torii Pharmaceutical Co Ltd | 6-HYDROXYBENZBROMARONE OR SALTING MEDICAL COMPOSITIONS CONTAINING THEREOF |
| US20080305169A1 (en) | 2006-05-26 | 2008-12-11 | Japan Tobacco Inc. | Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds |
| BRPI0809843A2 (pt) | 2007-04-26 | 2014-09-23 | Auspex Pharmaceuticals Inc | "composto, composição farmacêutica e uso de um composto" |
| TWI377944B (en) | 2007-06-05 | 2012-12-01 | Hanmi Holdings Co Ltd | Novel amide derivative for inhibiting the growth of cancer cells |
| US8791077B2 (en) | 2008-05-22 | 2014-07-29 | Astrazeneca Ab | Method for treating hyperuricemia employing an SGLT2 inhibitor and composition containing same |
| JP5325065B2 (ja) | 2009-09-30 | 2013-10-23 | 株式会社富士薬品 | 新規フェノール誘導体 |
| IT1400609B1 (it) | 2010-05-10 | 2013-06-14 | Menarini Int Operations Lu Sa | Associazione di inibitori della xantina ossidasi e metformina e loro uso. |
| US10005750B2 (en) | 2010-10-06 | 2018-06-26 | J-Pharma Co., Ltd. | Developing potent urate transporter inhibitors: compounds designed for their uricosuric action |
| US20150031768A1 (en) | 2011-08-19 | 2015-01-29 | The Trustees Of Princeton University | C-halogen bond formation |
| US9060987B2 (en) * | 2011-11-04 | 2015-06-23 | Cymabay Therapeutics, Inc. | Methods for treating gout flares |
| US9962362B2 (en) | 2012-03-29 | 2018-05-08 | Children's Hospital Medical Center | Use of small molecule inhibitors targeting EYA tyrosine phosphatase |
| KR20210033067A (ko) * | 2012-06-04 | 2021-03-25 | 파마싸이클릭스 엘엘씨 | 브루톤 타이로신 키나아제 저해제의 결정 형태 |
| WO2014113407A2 (en) | 2013-01-16 | 2014-07-24 | Children's Hospital Medical Center | Use of small molecule inhibitors targeting eya tyrosine phosphatase |
| JP2016512817A (ja) | 2013-03-15 | 2016-05-09 | ヤンセン ファーマシューティカ エヌ．ベー． | 高尿酸血症の治療におけるカナグリフロジンとプロベネシドの組合せ |
| CN105579037A (zh) | 2013-05-31 | 2016-05-11 | 武田制药美国有限公司 | 用黄嘌呤氧化酶抑制剂治疗的方法和含黄嘌呤氧化酶抑制剂的组合物 |
| WO2015134467A1 (en) | 2014-03-05 | 2015-09-11 | The Trustees Of Princeton University | Methods and compositions for direct radioactive labeling of bio-active molecules and building blocks |
| MX2017001103A (es) | 2014-07-31 | 2017-04-27 | Merck Patent Gmbh | Derivados de indolizina que son aplicables a enfermedades neurodegenerativas. |
| CN104311516B (zh) * | 2014-09-16 | 2017-01-11 | 东北制药集团股份有限公司 | 一种苯溴马隆晶型b及其制备方法 |
| CN104262305B (zh) * | 2014-09-16 | 2016-06-08 | 东北制药集团股份有限公司 | 一种苯溴马隆晶型a及其制备方法 |
| CN113214198B (zh) | 2016-07-18 | 2022-12-23 | 广州瑞安博医药科技有限公司 | 用于治疗或预防与痛风或高尿酸血症相关的症状的化合物、组合物和方法 |
| WO2018090921A1 (zh) | 2016-11-16 | 2018-05-24 | 江苏新元素医药科技有限公司 | Urat1抑制剂及其应用 |
| WO2018110887A1 (ko) | 2016-12-14 | 2018-06-21 | 주식회사 엘지화학 | 헤테로 고리 화합물 및 이를 포함하는 유기 발광 소자 |
| WO2019195118A1 (en) | 2018-04-03 | 2019-10-10 | Children's Hospital Medical Center | Inhibitors of eya3-protein tyrosine phosphatase in dna damage repair signaling of pulmonary arterial hypertension |
| WO2019233459A1 (zh) | 2018-06-08 | 2019-12-12 | 江苏威凯尔医药科技有限公司 | 人表皮生长因子受体抑制剂及其制备方法和应用 |
| US20210338648A1 (en) | 2018-10-01 | 2021-11-04 | Astrazeneca Ab | Methods and compositions for reducing serum uric acid |
| CA3121624A1 (en) | 2018-12-06 | 2020-06-11 | Arthrosi Therapeutics, Inc. | Methods for treating or preventing gout or hyperuricemia |
| US12145917B2 (en) | 2018-12-06 | 2024-11-19 | Arthrosi Therapeutics, Inc. | Crystalline forms of a compound for treating or preventing gout or hyperuricemia |
| EP3962908A4 (en) | 2019-04-25 | 2022-10-26 | Board of Regents, The University of Texas System | HETEROCYCLIC INHIBITORS OF TYROSINE KINASE |
| EP3968989A4 (en) | 2019-05-14 | 2022-12-28 | Arthrosi Therapeutics, Inc. | COMPOUND FOR TREATMENT OF GOUT OR HYPERURICEMIA |
| CN112079830B (zh) | 2019-06-14 | 2023-12-22 | 上海翰森生物医药科技有限公司 | 含并环类衍生物抑制剂、其制备方法和应用 |
| WO2021252630A1 (en) | 2020-06-10 | 2021-12-16 | Arthrosi Therapeutics, Inc. | Methods for treating or preventing chronic kidney disease |
| CN111763215B (zh) | 2020-07-21 | 2021-05-18 | 成都海博为药业有限公司 | 一种具有含氮杂环结构的化合物及其制备方法和用途 |
| CN112729156A (zh) | 2020-12-24 | 2021-04-30 | 上海智能制造功能平台有限公司 | 一种人体数字化测量装置的数据拼接及系统标定方法 |
| CN114697265A (zh) | 2020-12-29 | 2022-07-01 | 华为技术服务有限公司 | 一种报文处理方法及装置 |
| IL310870A (en) | 2021-08-24 | 2024-04-01 | Arthrosi Therapeutics Inc | Quinazoline compounds for treatment of disease |
| US20250066316A1 (en) * | 2021-12-02 | 2025-02-27 | Arthrosi Therapeutics, Inc. | Crystalline forms of a compound for treating or preventing gout or hyperuricemia |
| CN118974028A (zh) | 2021-12-30 | 2024-11-15 | 广州瑞安博医药科技有限公司 | 用于治疗痛风或高尿酸血症的化合物的制备 |
-
2019
- 2019-12-05 US US17/311,249 patent/US12145917B2/en active Active
- 2019-12-05 IL IL283663A patent/IL283663B2/en unknown
- 2019-12-05 KR KR1020217021172A patent/KR102946486B1/ko active Active
- 2019-12-05 EA EA202191545A patent/EA202191545A1/ru unknown
- 2019-12-05 SG SG11202105745UA patent/SG11202105745UA/en unknown
- 2019-12-05 CN CN201980080515.8A patent/CN113226302B/zh active Active
- 2019-12-05 JP JP2021531047A patent/JP2022511800A/ja active Pending
- 2019-12-05 WO PCT/US2019/064784 patent/WO2020118113A1/en not_active Ceased
- 2019-12-05 EP EP19893127.1A patent/EP3890723A4/en active Pending
- 2019-12-05 BR BR112021010708-8A patent/BR112021010708A2/pt unknown
- 2019-12-05 AU AU2019394974A patent/AU2019394974B2/en active Active
- 2019-12-06 TW TW108144814A patent/TWI828817B/zh active
-
2024
- 2024-10-11 US US18/913,928 patent/US20250059150A1/en active Pending
- 2024-10-25 JP JP2024188449A patent/JP2025026857A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250059150A1 (en) | 2025-02-20 |
| IL283663B2 (en) | 2025-12-01 |
| US20220024889A1 (en) | 2022-01-27 |
| TW202039453A (zh) | 2020-11-01 |
| BR112021010708A2 (pt) | 2021-08-24 |
| CN113226302B (zh) | 2023-08-18 |
| KR20210100677A (ko) | 2021-08-17 |
| CN113226302A (zh) | 2021-08-06 |
| TWI828817B (zh) | 2024-01-11 |
| AU2019394974B2 (en) | 2025-08-28 |
| IL283663A (en) | 2021-07-29 |
| IL283663B1 (en) | 2025-08-01 |
| EP3890723A4 (en) | 2022-08-03 |
| CA3121913A1 (en) | 2020-06-11 |
| JP2025026857A (ja) | 2025-02-26 |
| US12145917B2 (en) | 2024-11-19 |
| AU2019394974A1 (en) | 2021-07-15 |
| JP2022511800A (ja) | 2022-02-01 |
| WO2020118113A1 (en) | 2020-06-11 |
| SG11202105745UA (en) | 2021-06-29 |
| KR102946486B1 (ko) | 2026-03-31 |
| EP3890723A1 (en) | 2021-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202191545A1 (ru) | Кристаллические формы соединения для лечения или профилактики подагры или гиперурикемии | |
| EA202191543A1 (ru) | Способы лечения или профилактики подагры или гиперурикемии | |
| IL285782A (en) | Compounds, compositions, and methods for treating disease | |
| CY1125145T1 (el) | Αναστολεις cd73 | |
| DK3814357T3 (da) | Heterocykliske og heteroarylforbindelser til behandling af huntingtons sygdom | |
| EP4017489C0 (en) | DGD1202 FOR THE TREATMENT OF KRAS-MUTATED CANCERS | |
| CY1124088T1 (el) | Παραγωγα 2,4-θειαζολιδινεδιονης στη θεραπεια διαταραχων του κεντρικου νευρικου συστηματος | |
| IL281427A (en) | Compounds for treating certain leukemias | |
| EA201790271A1 (ru) | Ингибиторы гликозидазы | |
| EA201992262A1 (ru) | Композиции и способы контроля нематод | |
| EP3603636A4 (en) | COMPOSITION TARGETING S1PR4 TO PREVENT OR TREAT NON-ALCOHOLIC STEATOHEPATITIS | |
| IL290177A (en) | History of 4,2,1-oxadiazol-5-one for cancer therapy | |
| MX378739B (es) | Compuestos de 2-oxindol. | |
| EA202090180A1 (ru) | Композиции nk1-антагониста и способы лечения депрессии | |
| IL286437A (en) | Materials and methods for enhanced treatment and prevention of biofilms | |
| EP3755336A4 (en) | COMPOSITION TO PREVENT OR TREAT UVEITIS | |
| EA202090194A1 (ru) | Композиции статинов и способы их применения при лечении синуклеинопатий | |
| CY1110027T1 (el) | Συνδυασμος ενωσεων πυριμιδυλαμινοβενζαμιδης και ιματινιβης για τη θεραπεια ή την προληψη των νεοπλασματικων ασθενειων | |
| EP4034108A4 (en) | AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | |
| EP3955927A4 (en) | COMPOSITIONS AND METHODS FOR TREATING, AMOUNTING AND PREVENTING H. PYLORI INFECTIONS | |
| EP3848029A4 (en) | Medicine composition for treating cerebral infarction | |
| EP3777848C0 (en) | COMPOSITION FOR THE PREVENTION OR TREATMENT OF A STROKE | |
| IL291640A (en) | Compounds of 1,8-naphthyridin-2-one for the treatment of autoimmune disease | |
| SA522431572B1 (ar) | مركب بيريميدين-5-كربوكساميد | |
| IL282059A (en) | Abexitide for the treatment of hyperinsulinemic hypoglycemia |